ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
41 announcements with these filters
Windlas Biotech Limited confirmed it does not fall under the 'Large Corporate' category for the financial year 2026-27 as per SEBI criteria. The company reported zero outstanding borrowings as of March 31, 2026, and maintains an ICRA A+ credit rating.
Windlas Biotech Limited announced a share buyback of 4,70,000 equity shares at ₹1,000 per share via a tender offer, totaling ₹47.00 Crore. The buyback window opens on April 30, 2026, and closes on May 7, 2026. This corporate action aims to return capital to shareholders at a significant premium.
Windlas Biotech Limited announced a ₹47 Crore share buyback via tender offer at ₹1,000 per share. The offer opens on April 30, 2026, and closes on May 7, 2026. The company intends to repurchase 4,70,000 shares, representing a significant return of capital to shareholders.
Windlas Biotech Limited announced a buyback of 4,70,000 equity shares at ₹1,000 per share, totaling ₹47 Crore via a tender offer. The buyback opens on April 30, 2026, and closes on May 7, 2026. Promoters will not participate in the offer, which aims to return capital to shareholders.
Windlas Biotech Ltd has issued a Letter of Offer for the buyback of up to 4,70,000 equity shares at ₹1,000 per share. The ₹47 Crore buyback will be conducted via the tender offer route from April 30 to May 07, 2026, for eligible shareholders as on the April 24 record date.
Windlas Biotech Limited announced a buyback of 4,70,000 equity shares at ₹1,000 per share, totaling ₹47 Crore. The buyback will be conducted via a tender offer on a proportionate basis for shareholders as of the April 26, 2026 record date.
Windlas Biotech Limited's board approved a ₹47 Crore equity share buyback via tender offer at ₹1000 per share. The company proposes to buy back 4,70,000 shares, representing 2% of its existing paid-up capital. The record date for the offer is fixed as April 24, 2026.
Windlas Biotech Limited approved a buyback of up to 4,70,000 equity shares at ₹1,000 per share, totaling ₹47 Crore. The buyback represents 2.23% of total equity and will be conducted via a tender offer. The record date for eligibility is fixed for April 24, 2026.
Windlas Biotech Limited has scheduled a Board Meeting for April 17, 2026, to consider a proposal for the buyback of equity shares. Trading window for designated persons is closed from April 1, 2026, until 48 hours after the conclusion of the meeting.
Windlas Biotech Limited has scheduled a Board meeting on April 17, 2026, to consider a proposal for the buyback of its fully paid-up equity shares. Trading window for designated persons remains closed from April 1, 2026, until 48 hours after the declaration of financial results for the year ended March 31, 2026.
Windlas Biotech Ltd submitted its quarterly certificate under SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The Registrar confirmed no physical shares exist and no dematerialization requests were received during the quarter. This is a routine administrative compliance filing with no material impact on operations.